Drug Profile
Research programme: membrane protein-targeting antibodies - MSM Protein Technologies/Merck Serono
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck Serono; MSM Protein Technologies
- Class Antibodies
- Mechanism of Action Immunogenetic modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Switzerland (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 30 Jul 2009 Early research in Undefined indication in Switzerland (Parenteral)